Abstract
Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Current Bioactive Compounds
Title: Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight
Volume: 4 Issue: 2
Author(s): Tanaji T. Talele
Affiliation:
Keywords: HCV NS5B polymerase, Allosteric pocket, Nonnucleoside inhibitors, Genotypes, Structure activity relationships
Abstract: Infections caused by hepatitis C virus (HCV) are a significant worldwide health problem for which novel therapies are urgently needed. One attractive and viable therapeutic target is HCV NS5B RNA dependent RNA polymerase (RdRp) since it is essential for the replication of the viral genome of HCV. The hunt for nonnucleoside inhibitors (NNIs) of HCV NS5B polymerase has led to the identification of several allosteric pockets. However, because the topographical features of these binding sites vary across and even within diverse HCV genotypes, the discovery of new antiviral drugs capable of inhibiting HCV RdRp in the face of variable binding pockets becomes a challenging endeavor. This review focuses on recent accomplishments in the development of new NNIs of HCV NS5B polymerase and on their binding mechanisms to the respective allosteric pockets. Potential difficulties surrounding the discovery of future NNIs targeted to different allosteric pockets of HCV NS5B and to HCV NS5B from different genotypes are also discussed.
Export Options
About this article
Cite this article as:
Talele T. Tanaji, Multiple Allosteric Pockets of HCV NS5B Polymerase and its Inhibitors: A Structure Based Insight, Current Bioactive Compounds 2008; 4 (2) . https://dx.doi.org/10.2174/157340708785294217
DOI https://dx.doi.org/10.2174/157340708785294217 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adult Neural Stem Cells: Response to Stroke Injury and Potential for Therapeutic Applications
Current Stem Cell Research & Therapy Evaluation of the Pharmacological Descriptors Related to the Induction of Antidepressant Activity and its Prediction by QSAR/QRAR Methods
Mini-Reviews in Medicinal Chemistry Dropless Cataract Surgery: An Overview
Current Pharmaceutical Design Genetic Susceptibility to Behavioural and Psychological Symptoms in Alzheimer Disease
Current Alzheimer Research The Yin and Yang of CD4+ Regulatory T Cells in Autoimmunity and Cancer
Current Medicinal Chemistry Role of Fibroblast Growth Factor 21 (FGF21) in the Regulation of Statural Growth
Current Pediatric Reviews Angiotensin II: Role in Skeletal Muscle Atrophy
Current Protein & Peptide Science Sigma Receptor Activation Reduces Infarct Size at 24 Hours After Permanent Middle Cerebral Artery Occlusion in Rats
Current Neurovascular Research Hereditary Haemorrhagic Telangiectasia: A Rare Disease As A Model for the Study of Human Atherosclerosis
Current Pharmaceutical Design Monoclonal Antibodies to Treat Graft-Versus-Host Disease
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Potential Role of IL-18 in the Immunopathogenesis of AIDS, HIVAssociated Lipodystrophy and Related Clinical Conditions
Current HIV Research The Many Antithrombotic Actions of Nitric Oxide
Current Drug Targets Anthrax Fusion Protein Therapy of Cancer
Current Protein & Peptide Science Creating Chemical Diversity to Target Protein Kinases
Combinatorial Chemistry & High Throughput Screening Progress of In Vivo Electroporation in the Rodent Brain
Current Gene Therapy Thalidomide in Multiple Myeloma
Current Pharmaceutical Biotechnology MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions
Current Drug Metabolism